• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Unichem gets US FDA approval for Atenolol and Chlorthalidone Tablets

expresspharmaNovember 30, 2020

Tag: Unichem Laboratories , FDA , Atenolol , Chlorthalidone

Unichem Laboratories has received ANDA approval for its Atenolol and Chlorthalidone Tablets, USP 50 mg/25 mg and 100 mg/25 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TENORETIC (atenolol and chlorthalidone) Tablets of Alvogen Malta Operations.

Atenolol and Chlorthalidone Tablets are indicated for the treatment of hypertension, to lower blood pressure.

The product will be commercialized from Unichem’s Ghaziabad Plant.

Previous:Global Demand For COVID-19 Products Presents Huge Opportunities for the Biomanufacturing Sector

Next:Dr Reddy’s to acquire select anti-allergy brands from Glenmark in Russia and other CIS countries

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Unichem gets US FDA approval for Atenolol and Chlorthalidone Tablets | Pharmasources.com

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA

PR NEWSWIRENovember 22, 2024

Ascentage Pharma announced that a NDA for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575)has been accepted and recommended the Priority Review designation CDE and NMPA.

You may like
More>>

Mitomycin ( FDA)

Mitomycin ( FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Atenolol

Atenolol
Clozapine (FDA)

Clozapine (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Azilsartan Medoxomil + Chlorthalidone

Azilsartan Medoxomil + Chlorthalidone
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Deltamine (FDA)

Deltamine (FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service